News | April 07, 2024
Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
An accomplished R&D leader and champion of the application of AI to drug discovery
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)